In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...
The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...
After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...
Zacks Investment Research on MSN
ALDX crashes 71% as FDA issues third CRL for dry eye disease drug NDA
Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...
Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset activity within minutes versus existing therapies requiring weeks to months.
Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.
A new interpretation of a 3,500-year-old medical text from Egypt suggests that ancient physicians might have bathed patients' eyeballs in human breast milk to treat certain ophthalmic conditions. And ...
Metformin use in people with diabetes was linked to a significantly lower risk of developing intermediate age-related macular degeneration.
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results ...
Study reveals that 77% of patients with moderate-to-severe dry eye disease exhibit discordance between clinical signs and symptoms.
A spike in temperatures highlights the felt reality and scientific certainty of climate change. So why is this still such a difficult conversation?
With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results